Business
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., have submitted a supplemental application to ANMAT, the Argentinian health regulatory agency, and COFEPRIS, the Mexican health regulatory agency, respectively, seeking approval for an additional indication f
About this update from Incyte Corporation
[{"type":"image","alt":"Knight Therapeutics","displaySize":"","headline":null,"caption":"Knight Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nIp9.tgiE4HLNmyfEs7DtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63","width":300,"height":79}},"lazy":false},{"type":"text","content":"MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., have submitted a supplemental application to ANMAT, the Argentinian health regulatory agency, and COFEPRIS, the Mexican health regulatory agency, respectively, seeking approval for an additional indication for MINJUVI® (tafasitamab), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1–3a) after at least one prior line of systemic therapy.","length":737,"tagName":"p"},{"type":"text","content":"Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ: INCY) in September 2021 for tafasitamab (commercialized as MONJUVI® (tafasitamab-cxix) in the United States and MINJUVI® ex-USA) across Latin America. Knight has launched MINJUVI® in Brazil, Mexico and Argentina for use in combination with lenalidomide, followed by MINJUVI® monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT). In March 2026, Knight announced the approval and launch of MINJUVI® in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory FL in Brazil.1","length":742,"tagName":"p"},{"type":"text","content":"“In past two years we have launched MINJUVI® for the treatment of diffuse large B-cell lymphoma in Brazil, Mexico, and Argentina. More recently, MINJUVI® received regulatory approval for the treatment of refractory follicular lymphoma in Brazil,” said...